- Company
- Potential changes to reimb policy for new anticancer drugs
- by Moon, sung-ho Jul 16, 2025 06:08am
- Multinational pharmaceutical companies are actively pursuing to secure reimbursement for their anti-cancer drugs as first-line treatment options. Based on accumulated clinical research, companies are competitively applying for reimbursement from the government, putting in all efforts to accomplish this by the second half of this year. R
- Company
- Polivy’s reimbursement for DLBLC will soon be reviewed
- by Eo, Yun-Ho Jul 15, 2025 06:08am
- Polivy, the first first-line treatment introduced for diffuse large B-cell lymphoma (DLBCL) in 20 years, is entering the first stage of its renewed bid for reimbursement in Korea. According to industry sources, Polivy (polatuzumab vedotin), a treatment developed by Roche Korea for relapsed or refractory diffuse large B-cell lymphoma (DLBC
- Company
- Various immunotherapies attempt to treat Alzheimer’s
- by Son, Hyung Min Jul 15, 2025 06:06am
- A series of immunotherapy candidates are showing promise in the field of Alzheimer's disease treatment. With the limitations of existing antibody therapies becoming apparent, multinational pharmaceutical companies are attempting approaches targeting new immune pathways. In particular, pipelines targeting innate immune regulation, such as NK cell
- Company
- Omjjara’s reimbursement progress gains attention
- by Eo, Yun-Ho Jul 14, 2025 06:04am
- Attention is turning to whether progress will be made in the reimbursement listing process for the new myelofibrosis drug, Omjjara. Omjjara (momelotinib), a myelofibrosis treatment developed by GSK Korea, passed the Health Insurance Review and Assessment Service's Cancer Disease Review Committee in March and is currently awaiting submissi
- Company
- Aftermath of Januvia's price cut…MSD-CKD compensation fight
- by Son, Hyung Min Jul 14, 2025 06:04am
- Regarding transaction for price difference compensation following the drug price reduction for the diabetes treatment Januvia, Chong Kun Dang and MSD Korea have not reached agreement during negotiation for nearly two years. While the distribution industry continues to demand compensation for losses incurred due to the drug price cut, the lac
- Company
- Daiichi Sankyo and Ono Pharmaceutical see surge in sales
- by Son, Hyung Min Jul 14, 2025 06:03am
- Japanese pharmaceutical companies operating in South Korea saw overall sales growth last year. All seven companies surveyed achieved year-on-year sales growth, with Daiichi Sankyo Korea and Ono Pharma Korea leading the way with double-digit growth rates. However, in terms of operating profits, the companies showed mixed emotions. According to
- Company
- Bimzelx may be prescribed at general hospitals in KOR
- by Eo, Yun-Ho Jul 11, 2025 06:12am
- The new psoriasis drug Bimzelx may be prescribed at general hospitals in Korea. According to industry sources, UCB Pharma Korea's Bimzelx (bimekizumab) has been approved by the Drug Committees (DCs) of major hospitals nationwide, including tertiary hospitals like Seoul Asan Medical Center and Severance Hospital as well as major hospitals
- Company
- Gastric cancer-targeted therapy 'Vyloy' seeks reimb again
- by Eo, Yun-Ho Jul 10, 2025 06:10am
- Vyloy, a gastric cancer-targeted therapy, is once again vying for inclusion in the National Health Insurance reimbursement list. According to industry sources, Astellas Pharma Korea recently submitted a reimbursement application for Vyloy (zolbetuximab), a targeted treatment for Claudin 18.2-positive gastric cancer. Vyloy did not pass
- Company
- Ono Pharma Korea’s sales double in 4 years with Opdivo
- by Son, Hyung Min Jul 10, 2025 06:09am
- Ono Pharmaceutical Korea continued its sales growth, powered by its immuno-oncology drug Opdivo. The company's sales doubled in 4 years. The company is preparing for the expiration of Opdivo's patent by securing a diverse pipeline of new anticancer drugs, including antibody-drug conjugates (ADCs) and novel immuno-oncology drugs with different me
- Company
- Credit ratings for Samsung Biologics·JW Holdings↑
- by Kim, Jin-Gu Jul 10, 2025 06:08am
- Major pharmaceutical and biotech companies (biopharma companies) are facing varying differing credit ratings and outlooks. While Samsung Biologics and JW Holdings received upward credit ratings, Handok was downgraded. Dong-A ST's credit rating outlook shifted from 'stable' to 'negative'. Credit rating agencies explained that these resul
